Literature DB >> 2991591

Epstein-Barr virus-encoded protein found in plasma membranes of transformed cells.

K P Mann, D Staunton, D A Thorley-Lawson.   

Abstract

We have developed monoclonal antibodies to a 63,000-molecular-weight protein (p63) which is the product of the most abundant messenger RNA in Epstein-Barr virus-transformed cells and shown that the protein is associated specifically with plasma membranes. It was also found to be associated with the other membrane fractions and was found in all Epstein-Barr virus-transformed cells tested. In addition, p63 was present in virions, resulting in transient, early appearance in newly infected cells. Newly synthesized p63 was detected at the time cells underwent blast transformation (48 to 72 h postinfection). The possible role of this protein in transformation and as a target for cell-mediated cytotoxicity is discussed.

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 2991591      PMCID： PMC255052     

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  47 in total

1.  Biological and biochemical observations on isolates of EB virus from the malignant epithelial cells of two nasopharyngeal carcinomas.

Authors:  D H Crawford; M A Epstein; G W Bornkamm; B G Achong; S Finerty; J L Thompson
Journal:  Int J Cancer       Date:  1979-09-15       Impact factor: 7.396

2.  Epstein-Barr virus-specific RNA. III. Mapping of DNA encoding viral RNA in restringent infection.

Authors:  A L Powell; W King; E Kieff
Journal:  J Virol       Date:  1979-01       Impact factor: 5.103

3.  Reversible inhibition by phosphonoacetic acid of human B lymphocyte transformation by Epstein-Barr virus.

Authors:  D A Thorley-Lawson; J L Strominger
Journal:  Virology       Date:  1978-05-15       Impact factor: 3.616

4.  Two related but differentially expressed potential membrane proteins encoded by the EcoRI Dhet region of Epstein-Barr virus B95-8.

Authors:  G S Hudson; P J Farrell; B G Barrell
Journal:  J Virol       Date:  1985-02       Impact factor: 5.103

5.  Fatal infectious mononucleosis in a family.

Authors:  R S Bar; C J DeLor; K P Clausen; P Hurtubise; W Henle; J F Hewetson
Journal:  N Engl J Med       Date:  1974-02-14       Impact factor: 91.245

6.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

7.  Epstein-Barr virus-specific cytotoxic T-cell clones restricted through a single HLA antigen.

Authors:  L E Wallace; A B Rickinson; M Rowe; M A Epstein
Journal:  Nature       Date:  1982-06-03       Impact factor: 49.962

8.  Identification of Epstein-Barr nuclear antigen polypeptide in mouse and monkey cells after gene transfer with a cloned 2.9-kilobase-pair subfragment of the genome.

Authors:  D K Fischer; M F Robert; D Shedd; W P Summers; J E Robinson; J Wolak; J E Stefano; G Miller
Journal:  Proc Natl Acad Sci U S A       Date:  1984-01       Impact factor: 11.205

9.  Differential reactivity of human serums with early antigens induced by Epstein-Barr virus.

Authors:  W Henle; G Henle; B A Zajac; G Pearson; R Waubke; M Scriba
Journal:  Science       Date:  1970-07-10       Impact factor: 47.728

10.  Suppression of in vitro Epstein-Barr virus infection. A new role for adult human T lymphocytes.

Authors:  D A Thorley-Lawson; L Chess; J L Strominger
Journal:  J Exp Med       Date:  1977-08-01       Impact factor: 14.307
View more
  124 in total

1.  Epstein-Barr virus recombinants from BC-1 and BC-2 can immortalize human primary B lymphocytes with different levels of efficiency and in the absence of coinfection by Kaposi's sarcoma-associated herpesvirus.

Authors:  A J Aguirre; E S Robertson
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

2.  The late lytic LMP-1 protein of Epstein-Barr virus can negatively regulate LMP-1 signaling.

Authors:  K D Erickson; J M Martin
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

3.  Control of cell cycle entry and apoptosis in B lymphocytes infected by Epstein-Barr virus.

Authors:  L C Spender; E J Cannell; M Hollyoake; B Wensing; J M Gawn; M Brimmell; G Packham; P J Farrell
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

4.  Epstein-barr virus (EBV) nuclear protein 2-induced disruption of EBV latency in the Burkitt's lymphoma cell line Akata: analysis by tetracycline-regulated expression.

Authors:  S Fujiwara; Y Nitadori; H Nakamura; T Nagaishi; Y Ono
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

5.  Epstein-Barr virus nuclear protein 2 is a key determinant of lymphocyte transformation.

Authors:  J I Cohen; F Wang; J Mannick; E Kieff
Journal:  Proc Natl Acad Sci U S A       Date:  1989-12       Impact factor: 11.205

6.  Conserved regions in the Epstein-Barr virus leader protein define distinct domains required for nuclear localization and transcriptional cooperation with EBNA2.

Authors:  R Peng; J Tan; P D Ling
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

7.  Contributions of CTCF and DNA methyltransferases DNMT1 and DNMT3B to Epstein-Barr virus restricted latency.

Authors:  David J Hughes; Elessa M Marendy; Carol A Dickerson; Kristen D Yetming; Clare E Sample; Jeffery T Sample
Journal:  J Virol       Date:  2011-11-09       Impact factor: 5.103

8.  Evidence of an oncogenic gammaherpesvirus in domestic dogs.

Authors:  Shih-Hung Huang; Philip J Kozak; Jessica Kim; Georges Habineza-Ndikuyeze; Charles Meade; Anita Gaurnier-Hausser; Reema Patel; Erle Robertson; Nicola J Mason
Journal:  Virology       Date:  2012-03-08       Impact factor: 3.616

9.  Recognition of the Epstein-Barr virus-encoded nuclear antigens EBNA-4 and EBNA-6 by HLA-A11-restricted cytotoxic T lymphocytes: implications for down-regulation of HLA-A11 in Burkitt lymphoma.

Authors:  R Gavioli; P O De Campos-Lima; M G Kurilla; E Kieff; G Klein; M G Masucci
Journal:  Proc Natl Acad Sci U S A       Date:  1992-07-01       Impact factor: 11.205

10.  Epstein-Barr virus latent membrane protein transactivates the human immunodeficiency virus type 1 long terminal repeat through induction of NF-kappa B activity.

Authors:  M L Hammarskjöld; M C Simurda
Journal:  J Virol       Date:  1992-11       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.